Boston starts drug-eluting stent trial enrolment:
This article was originally published in Clinica
Boston Scientific (Massachusetts, US) has begun the enrolment phase of its 532-patient, international study to assess its drug-eluting stent. The TAXUS II trial, which is being led by cardiologist Antonio Colombo, of EMO Centro Cuore Colombus, Milan, Italy, will investigate the use of Boston's paclitaxel-eluting stent technology as a means of preventing restenosis. Data from the trial will be used to support an application to market the product in Europe and in other international markets, the firm says.